News

The trial met its primary endpoint of demonstrating a clinically meaningful and a statistically significant increase in overall survival (“OS”), in the intention-to-treat (ITT) population of patients treated

The UK's Competition and Markets Authority (CMA) said both the firms entered into agreements under which Actavis UK incentivised Concordia not to enter the market with its own

Under the deal, the companies will jointly develop and commercialise MEDI8897, a highly potent monoclonal antibody (mAb) that neutralises RSV by binding the RSV fusion (F) protein expressed on

Ocaliva has been conditionally approved in the European Union for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate

Ataluren was generally well tolerated and ACT CF confirmed a favorable safety profile for ataluren, which has now been used by more than 1,000 patients across multiple indications.

The study demonstrated that the combination of Perjeta (pertuzumab), Herceptin  (trastuzumab) and chemotherapy (the Perjeta-based regimen) reduced risk of recurrence of invasive disease or death (invasive disease-free survival) in people

The NDA was granted Priority Review and has been given a Prescription Drug User Fee Act (PDUFA) action date of Aug. 30, 2017. Celgene completed the NDA submission

APS is a disorder of the immune system, where abnormal antibodies, called antiphospholipid antibodies (aPL) are produced. These bind to beta-2-glycoprotein (beta-2-GPI) in the blood and increase the

The study evaluated the efficacy of Blincyto versus standard of care (SOC) chemotherapy in high-risk adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia